This morning, Chardan Healthcare Acquisition Corp. (CHACU) filed for a $70 million, Chardan-backed SPAC focusing on Healthcare companies in North America. Chardan Healthcare will be led by senior members of Chardan Capital Markets, a veteran SPAC underwriter.
Gbola Amusa, who has served as Partner, Director of Research, and Head of Healthcare Equity Research at Chardan Capital Markets since December 2014, will be Chairman of the Board for this team and Jonas Grossman, the current Partner and Head of Capital Markets for Chardan, will be leading as President and CEO. Finally, George Kaufman, who is currently Managing Director and Head of Investment Banking, will be CFO and Head of Strategy.
Looking at this SPAC’s structure, these terms look very aggressive. Of the five deals currently on file (CF Finance, Monocle, Schultze, Andina III, Chardan Healthcare), only Chardan Healthcare is offering a 1/2 share in their warrant. AND, it’s the only SPAC on file with a 24 month life. On top of that, the warrant trigger to call the warrants for redemption is set at >$16.00, rather than the standard >$18.00. (We’ll be putting together a comparison of all five, shortly)
Additionally, you will also notice that the underwriting fee is not being split as upfront/deferred. That’s because Chardan has decided to take a flat fee of just $500K, which makes sense since this is their deal and by lowering the underwriting fee, it reduces the amount of at-risk capital needed to bring the trust to 100%. However, they are purchasing their at-risk capital warrants at $0.40.
Since there is a conflict of interest with Chardan Capital Markets underwriting a SPAC with Chardan as a sponsor, Chardan Healthcare will be utilizing B. Riley FBR as their Qualified Independent Underwriter, but again, just like CF Finance, the QIU is not on the cover. That’s branding, folks. Both Chardan and Cantor want their deals to be 100% their own.
It remains to be seen if Chardan Healthcare will stick with these terms given the comparison to the other four SPACs currently on file. It’s aggressive for sure, but it’s a lot easier to start high rather than work your way up from low.
Chardan is sole book-running manager.
Loeb & Loeb LLP and Schiff Hardin LLP are issuer’s counsel and underwriter’s counsel, respectively.
This year has seen a variety of innovations for SPACs to continue the lifespan beyond their traditional search windows. In general, this creativity is welcome as long as investors get their chance to have a say and a redemption opportunity at the appropriate time. But, in the second half of 2024, some SPACs have not...
At the SPAC of Dawn US market futures are green after the gut punch of news on slowing rate cuts, but there are now fresh concerns that the post-election rally may be short-lived. New clouds could be on the horizon as well in the form of a potential government shutdown as well as the implementation...
At the SPAC of Dawn As the countdown to the Fed’s 2 pm ET rate cut decision tick down, the space sector continues to be one of the main areas of SPAC activity most unblemished from the volatility ahead of the move. AST SpaceMobile (NASDAQ:ASTS) and Intuitive Machines (NASDAQ:LUNR) each finished up significantly in Tuesday...
At the SPAC of Dawn De-SPACs have continued to be able to raise significant capital this quarter. This morning, two more companies launched share offerings while another pulled in private capital funding from a strategic partner. This is a good sign for the ability of SPACs to raise PIPE capital for any forthcoming deals as...
At the SPAC of Dawn SPACs have scheduled eight extension votes ahead of what is frequently a busy Christmas week for the market, although none of these are set to complete a deal. There will also be plenty of economic indicator releases this week, but only manufacturing numbers slated for this morning. Meanwhile the market’s...